Clinical and Pharmacological Effects of Apixaban Dose Adjustment in the ARISTOTLE Trial
- 17 March 2020
- journal article
- research article
- Published by Elsevier BV in Journal of the American College of Cardiology
- Vol. 75 (10), 1145-1155
- https://doi.org/10.1016/j.jacc.2019.12.060
Abstract
No abstract availableFunding Information
- Bristol-Myers Squibb Co
This publication has 31 references indexed in Scilit:
- Efficacy and Safety of Apixaban Compared With Warfarin at Different Levels of Predicted International Normalized Ratio Control for Stroke Prevention in Atrial FibrillationCirculation, 2013
- Apixaban versus Warfarin in Patients with Atrial FibrillationThe New England Journal of Medicine, 2011
- Rivaroxaban versus Warfarin in Nonvalvular Atrial FibrillationThe New England Journal of Medicine, 2011
- Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairmentEuropean Heart Journal, 2011
- Warfarin Dosing in Patients With Impaired Kidney FunctionAmerican Journal of Kidney Diseases, 2010
- Apixaban for Reduction In Stroke and Other ThromboemboLic Events in Atrial Fibrillation (ARISTOTLE) trial: Design and rationaleAmerican Heart Journal, 2010
- Dabigatran versus Warfarin in Patients with Atrial FibrillationThe New England Journal of Medicine, 2009
- Kidney Function Influences Warfarin Responsiveness and Hemorrhagic ComplicationsJournal of the American Society of Nephrology, 2009
- Adverse Impact of Bleeding on Prognosis in Patients With Acute Coronary SyndromesCirculation, 2006
- Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patientsJournal of Thrombosis and Haemostasis, 2005